All In Biotech

Drug Trial Radar · NCT05519475

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Feb 9, 2023

Primary completion

Apr 27, 2028

Study completion Dec 7, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Aug 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH). MASH is a form of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). MASH occurs when fat builds up in liver cells, damaging them, and making the liver inflamed and stiff from fibrosis (scar tissue). MASH can progress to cirrhosis (long term scarring) and liver failure (when the liver cannot perform its job). The aim of the study is to see the effect of the study drug on lessening liver scarring related to MASH. The study is looking at several other research questions, including: * How ALN-HSD works to improve liver function and lessen MASH-related inflammation in the liver * What side effects may happen from receiving the study drug * How much study drug and study drug metabolites (byproduct of the body breaking down the study drug) are in the blood at different times * Better understanding of the study drug and MASH

Conditions

  • Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

Interventions

  • ALN-HSDDrug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in quantitative liver Fibrosis (qFibrosis)Time frame: Baseline to week 52

Locations

71 sites in 4 countries. Site status is shown where the registry gives one.

  • The Institute for Liver Health II LLC DBA Arizona Clinical Trials - Flagstaff

    Flagstaff, Arizona

  • The Institute for Liver Health II LLC DBA Arizona Liver Health - Peoria

    Peoria, Arizona

  • Adobe Clinical Research

    Tucson, Arizona

  • Arizona Liver Health - Tucson

    Tucson, Arizona

  • The Institute for Liver Health II LLC dba Arizona Liver Health

    Tucson, Arizona

  • Del Sol Research Management, LLC

    Tucson, Arizona

  • San Fernando Valley Health Institute

    Canoga Park, California

  • Velocity Clinical Research

    Chula Vista, California

  • Southern California Research Center

    Coronado, California

  • Velocity Clinical Research

    Gardena, California

  • Velocity Clinical Research - Huntington Park

    Huntington Park, California

  • Om Research Llc

    Lancaster, California

  • Ark Clinical Research - Long Beach

    Long Beach, California

  • Ark Clinical Research, LLC

    Long Beach, California

  • Velocity Clinical Research - Westlake

    Los Angeles, California

  • Clinnova Research Solutions

    Orange, California

  • Knowledge Research Center, St. Joseph's Medical Tower

    Orange, California

  • National Research Institute

    Panorama City, California

  • California Liver Research Institute

    Pasadena, California

  • Cadena Care Inst.

    Poway, California

  • Inland Empire Clinical Trials

    Rialto, California

  • Precision Research Institute - San Diego

    San Diego, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • Synergy Healthcare LLC

    Bradenton, Florida

  • Evolution Clinical Trials

    Hialeah Gardens, Florida

  • Health Awareness, inc.

    Jupiter, Florida

  • Miami Clinical Research

    Miami, Florida

  • International Medical Investigational Centers (IMIC) Incorporated

    Miami, Florida

  • Genoma Research Group, Inc.

    Miami, Florida

  • US Associates in Research, LLC

    Miami, Florida

  • Med Research of Florida, LLC

    Miami, Florida

  • Charter Research LLC - Orlando

    Orlando, Florida

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • Deaconess Clinic - GI Specialty Center

    Newburgh, Indiana

  • Tandem Clinical Research

    Metairie, Louisiana

  • Mercy Medical Center

    Baltimore, Maryland

  • GI Associates

    Flowood, Mississippi

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Irving Medical Center

    New York, New York

  • Geisinger Medical Center

    Danville, Pennsylvania

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.